Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 19, 2021 9:06am
157 Views
Post# 32324882

RE:RE:RE:RE:Convertible pricing

RE:RE:RE:RE:Convertible pricingWith 1.5% insider ownership they don't have much to worry about even if the SP stay at current levels indefinitely they still pick up their multi six figures and bonuses so yes we carry the cost when many of us are heavily invested in the company for many years when the stock market has gone up for the last decade.
They have all academic background in many areas and years of experience so how is that with folks in this board come out with constructive suggestions re how to handle the market they just refuse to make any changes to their failing strategy?
Did they learn at university and during years of working in the field that when you fail just accept it rather than showing the flexibility and act accordingly...

juniper88 wrote: To me, this was a lazy solution to the financial issues managemnt was facing. And as Wino wrote "it is the cost we bear".  Other than Dawn, management doesn't have that much skin in the game.  Theoretically this is a hit on the reputation of the company/management, but then again they didn't seem to be able to market the company's shares anyway.  I am sure management believes that if the cancer and NASH trials work out then the market will forgive.So, really, not much harm done to the company, just the current share holders. Just my opinion, but that is what I believe management was thinking.




SPCEO1 wrote: Sounds about right to me.

Wino115 wrote:

I honestly think they worked themselves into a frenzy looking at upcoming spending, the lack of past stock price response to seemingly good news and market froth.   You can call that sensible, conservative, emotional, non-analytical.  But in the end, it is the cost we bear for their past inability to communicate a co Vinci g case as to why the future is bright and they are entering massive markets.  They've just failed that test and more or less knew they couldn't flip a switch and repair that.  The last thing I'll say about this is that we were ahead of them in saying how they needed a much more robust and convincing pitch, a more concerted and funded PR and IR effort and should have been cultivating the market as they shed analysts over the last 2 years.  They did not even do the minimum necessary for a professional job and we unfortunately have paid for this lack of engagement with the US capital market and even Canada.  They stuck themselves in a narrow box and freaked out.

 

SPCEO1 wrote: I took a look to see if the convert bounced on the news of the offering. You would expect that the increased finances would give greater confidence to the people holding it as a bond, which is everyone holdinig right now, that the company will be better bale to pay it off when it comes due in a bit more than two years from now. But, basically, it has not moved at all from when the news of the offering came out. 

Now, the money raised was spcifically targetted to pay for the R&D over the next couple of years, so perhaps that is why the convert was unimpressed. But if the R&D programs all failed to move forward (cancer pahse I throws off a safety issue and the FDA reverses course on the NASH phase III) then the company would likely have enough money to redeem the convert. Perhaps this scenario was in TH's mind when they did this deal? It represents the most extreme downside scenario and, to me, is not what they should have been making their financing decision based on but they have more knowledge than us on the chances of success in cancer and the issues the FDA might yet have on NASH. If the risks are uglier than we realize, perhaps that motivated their call on this financing? 

I am trying to work hard at finding a reason why otherwise sensible people would have pursued this financing and, as you can see, it is not an easy task,
 

 

 


 




<< Previous
Bullboard Posts
Next >>